Aqilion focuses on diseases caused by chronic inflammation and dysfunctional immunological reactions
We explore novel scientific findings describing the biology behind the diseases and focus on developing new innovative treatments. Our mission is clear, we identify opportunities based on solid research resting on a firm biological foundation offering both clinical relevance and patient benefit.
Sarah Fredriksson, CEO, presents Aqilion:
Aqilion is a biotech company developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions. The company is active in early phases of drug discovery, from idea stage to early clinical development.
Main focus is to expand Aqilion’s project portfolio within chronic inflammation and immunology.
Two of Aqilion’s discovery projects have been created out of an interest for one of the key inflammatory processes of the innate immune system, the formation of multiprotein complexes called inflammasomes.
Press releases
-
March 24, 2021Aqilion strengthens the company’s Alnitak pharmaceutical project in chronic inflammation through closer collaboration with Örebro University researchers
-
March 24, 2021Aqilion stärker bolagets läkemedelsprojekt Alnitak inom kronisk inflammation genom fördjupat samarbete med forskare vid Örebro universitet